Published in J Clin Oncol on April 09, 2012
Ovarian cancer treatment: The end of empiricism? Cancer (2015) 0.85
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene (2015) 0.84
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Mol Clin Oncol (2013) 0.83
Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression. Diagn Pathol (2016) 0.82
Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecol Oncol (2015) 0.82
Patterns of spread of clear cell ovarian cancer: Case report and case series. Gynecol Oncol Case Rep (2013) 0.78
Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011. J Gynecol Oncol (2016) 0.77
Recent advances in systemic treatments for ovarian cancer. Cancer Imaging (2012) 0.76
Oncology scan - gynecological cancers: new treatments, old treatments, imaging, and meta-analyses. Int J Radiat Oncol Biol Phys (2013) 0.75
Clear cell carcinoma arising from abdominal wall endometriosis - Brief report and review of the literature. Gynecol Oncol Rep (2017) 0.75
Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional Experience. J Obstet Gynaecol India (2016) 0.75
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst (2005) 5.65
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (2008) 2.09
Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol (2013) 1.94
Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol (2011) 1.91
Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol (2010) 1.87
Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol (2013) 1.63
The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer (2009) 1.60
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer (2005) 1.47
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer (2009) 1.43
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol (2008) 1.32
Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys (2009) 1.30
Evolutionary concepts in biobanking - the BC BioLibrary. J Transl Med (2009) 1.29
Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer (2011) 1.27
Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol (2009) 1.25
The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol (2012) 1.23
Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol (2003) 1.21
Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol (2005) 1.20
Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol (2006) 1.18
Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer (2009) 1.14
Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol (2006) 1.13
The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol (2004) 1.11
Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol (2009) 1.10
Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg (2007) 1.05
Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum. Int J Radiat Oncol Biol Phys (2004) 1.03
Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol (2010) 1.02
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res (2012) 1.01
Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg (2006) 1.00
Better therapeutic trials in ovarian cancer. J Natl Cancer Inst (2014) 1.00
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol (2009) 1.00
Comparison of two diverse populations, British Columbia, Canada, and Ardabil, Iran, indicates several variables associated with gastric and esophageal cancer survival. J Gastrointest Cancer (2011) 0.99
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res (2009) 0.98
Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl Immunohistochem Mol Morphol (2014) 0.98
Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol (2015) 0.97
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer (2010) 0.96
HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg (2010) 0.94
New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. Obstet Gynecol (2012) 0.93
Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. Am J Surg Pathol (2015) 0.91
Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol (2007) 0.91
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. Am J Surg (2012) 0.88
Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction. PLoS One (2013) 0.86
Chronic advanced gastric cancer: clinicopathologic analysis of survival data. Hum Pathol (2008) 0.86
The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecol Oncol (2013) 0.86
The impact of geographic variations in treatment on outcomes in ovarian cancer. Int J Gynecol Cancer (2013) 0.86
Induced pluripotency of human prostatic epithelial cells. PLoS One (2013) 0.86
Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol (2013) 0.86
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer (2013) 0.85
Bayesian adjustment for exposure misclassification in case-control studies. Stat Med (2010) 0.85
Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer (2010) 0.85
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful? Support Care Cancer (2013) 0.85
Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate (2013) 0.84
Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. Gynecol Oncol (2005) 0.84
Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol (2004) 0.84
Development of an agricultural job-exposure matrix for British Columbia, Canada. J Occup Environ Med (2002) 0.84
Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. Am J Surg Pathol (2012) 0.83
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer (2014) 0.83
Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch (2008) 0.82
The prognostic effect of ethnicity for gastric and esophageal cancer: the population-based experience in British Columbia, Canada. BMC Cancer (2011) 0.81
Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med (2013) 0.81
Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement. Am J Surg Pathol (2013) 0.81
Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol (2013) 0.81
Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer. Int J Radiat Oncol Biol Phys (2013) 0.81
Early-stage endometrioid ovarian carcinoma: population-based outcomes in British Columbia. Int J Gynecol Cancer (2014) 0.80
Identification of occupational cancer risks in British Columbia, Canada: a population-based case-control study of 1,155 cases of colon cancer. Int J Environ Res Public Health (2011) 0.80
The meaning of spirituality and spiritual care among the Hong Kong Chinese terminally ill. J Adv Nurs (2010) 0.80
The laboratory score/reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience. Am J Clin Pathol (2011) 0.80
Incidence of second metachronous head and neck cancers: population-based outcomes over 25 years. Laryngoscope (2014) 0.80
Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β. Int J Gynecol Pathol (2015) 0.79
Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience. J Clin Pathol (2011) 0.79
Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Can (2006) 0.78
A survey assessing the impact of a hospital-based general practice residency program on dentists and dental practice. Spec Care Dentist (2002) 0.78
Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer. Gynecol Oncol (2005) 0.78
Estimating nurses' exposures to ionizing radiation: the elusive gold standard. J Occup Environ Hyg (2008) 0.77
Occupational exposure and ovarian cancer risk. Cancer Causes Control (2014) 0.77
[Medication adherence rating scale]. Acta Med Port (2011) 0.77
Upregulation of PKD1L2 provokes a complex neuromuscular disease in the mouse. Hum Mol Genet (2009) 0.76
Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience. Gynecol Oncol (2008) 0.76
Inherited common variants in mitochondrial DNA and invasive serous epithelial ovarian cancer risk. BMC Res Notes (2013) 0.75
The significance of combination chemotherapy in epithelial ovarian cancer. Int J Gynecol Cancer (2014) 0.75
The role of the oncology nurse as the patient advocate. Can Oncol Nurs J (2012) 0.75
Strategies to use with interpreters in the clinical setting. Can Oncol Nurs J (2012) 0.75
An evaluation report of the nurse navigator services for the breast cancer support program. Can Oncol Nurs J (2015) 0.75
A nurse's perspective: working with South Asian women breast cancer survivors while delivering survivorship care plans. Can Oncol Nurs J (2014) 0.75
Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas. Int J Gynecol Cancer (2017) 0.75